X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
Europe
0
Canada
Australia
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761119
https://www.fiercepharma.com/pharma/setback-lundbeck-cgrp-migraine-drug-vyepti-hits-expansion-snag-sales-still-doubled
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761119
https://www.businesswire.com/news/home/20210419005515/en/New-Data-Presented-at-2021-American-Academy-of-Neurology-AAN-Annual-Meeting-Shows-VYEPTI%C2%AE-eptinezumab-jjmr-Demonstrated-Earlier-Time-to-Freedom-from-Headache-Pain-and-Absence-of-Most-Bothersome-Symptoms-Compared-to-Placebo-When-Initiated...
https://www.biospace.com/article/releases/positive-headline-results-from-the-vyepti-eptinezumab-jjmr-relief-study/
https://www.prnewswire.com/news-releases/orsini-pharmaceutical-services-selected-to-provide-vyepti-eptinezumab-jjmr--the-first-and-only-intravenous-preventive-treatment-for-migraine-301045273.html
https://www.fiercepharma.com/pharma/vyepti-launch-lundbeck-aims-to-overcome-challenges-crowded-migraine-field-exec
https://www.fiercepharma.com/pharma/migraine-prevention-field-set-for-even-more-competition-lundbeck-s-fda-nod
https://www.evaluate.com/vantage/articles/events/upcoming-events/go-or-no-go-esperions-double-whammy-and-look-priority
https://endpts.com/lundbecks-deborah-dunsire-didnt-just-want-an-ex-us-deal-for-alders-migraine-drug-she-wanted-the-whole-world/
http://www.globenewswire.com/news-release/2019/07/08/1879405/0/en/Alder-BioPharmaceuticals-to-Showcase-14-New-Data-Presentations-Demonstrating-Eptinezumab-s-Migraine-Prevention-and-Quality-of-Life-Impact-at-American-Headache-Society-Meeting.html
https://www.biopharmadive.com/news/amgen-launches-tv-spot-for-aimovig-in-tight-cgrp-market/539942/
https://www.fiercepharma.com/pharma/amgen-s-quick-aimovig-launch-has-implications-for-lilly-teva-and-alder-analyst
Market Place
Share 
